Kawakita Daisuke, Tada Yuichiro, Imanishi Yorihisa, Beppu Shintaro, Tsukahara Kiyoaki, Kano Satoshi, Ozawa Hiroyuki, Okami Kenji, Sato Yuichiro, Shimizu Akira, Sato Yukiko, Fushimi Chihiro, Takase Soichiro, Okada Takuro, Sato Hiroki, Otsuka Kuninori, Watanabe Yoshihiro, Sakai Akihiro, Ebisumoto Koji, Togashi Takafumi, Ueki Yushi, Ota Hisayuki, Shimura Tomotaka, Hanazawa Toyoyuki, Murakami Shingo, Nagao Toshitaka
Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Oncotarget. 2017 Jan 3;8(1):1083-1091. doi: 10.18632/oncotarget.13565.
The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.
改良格拉斯哥预后评分（mGPS）、中性粒细胞与淋巴细胞比值（NLR）及血小板与淋巴细胞比值（PLR）在涎腺导管癌（SDC）患者中的预后作用尚不清楚。我们对140例SDC患者进行了一项多机构回顾性队列研究。使用多变量比例风险模型评估这些血液学标志物对生存的影响。高mGPS（≥1）与较差的生存率显著相关（3年总生存率（OS）：16.7%对66.1%，p值=0.003；3年无进展生存率（PFS）：0.0%对27.9%，p值<0.001）。此外，高C反应蛋白（CRP）（≥0.39mg/dl）与较差的生存率显著相关（3年OS：32.1%对68.2%，p值=0.001；3年PFS：7.1%对31.1%，p值<0.001）。这些关联在针对既定预后因素进行调整的多变量分析中是一致的。尽管在多变量分析中我们还发现高NLR（≥2.5）与OS存在显著关联（风险比1.80；95%置信区间，1.05 - 3.08），但这种关联与PFS的结果不一致。此外，我们未发现PLR与生存存在显著关联。总之，我们发现mGPS、CRP和NLR被确定为与SDC患者生存相关的预后因素。
